Science at Sanofi

Access the full recording of the webinar to gain insights on Atopic Dermatitis, Bullous Pemphigoid, and practical applications from leading experts.

Discover the latest breakthroughs in pediatric infectious diseases, focusing on Pertussis, Polio and Hib protection.

Watch now to gain useful update on the latest in COPD diagnosis and management.​

Chapter 2: Pompe High-Risk Screening in Asia

Chapter 3: Treatment Strategies for Pompe Disease

Experts across Southeast Asia shared insights on influenza in older adults, highlighting disease burden, regional epidemiology, and the crucial role of vaccination for this high-risk group.

Watch now to gain clinical insights from real clinical cases in COPD management.​

Explore key clinical insights and trial data from ERS 2025, including breakthroughs in biologics for asthma and COPD, pediatric asthma management, and AI-enabled respiratory innovation. Curated for healthcare professionals.

LIBERTY AD CHRONOS was a randomized, double-blind, placebo-controlled trial in adults with 
moderate-to-severe atopic dermatitis

LIBERTY AD SOLO-CONTINUE was a randomized, double-blind, phase 3 clinical trial at 185 sites in North America, Europe, Asia, and Japan.

LIBERTY AD HAFT was a randomized phase 3 trial in adults and adolescents with moderate-to-severe hand and foot atopic dermatitis inadequately controlled with topicals.

Efficacy is shown through real-world evidence, skin bacterial microbiome, trans-epidermal water loss (TEWL), and nonatopic comorbidities.

Significant improvement in Worst Scratch and Itch NRS score, Skin Clearance, and Children’s Dermatology Life Quality Index (CDLQI).

Efficacy is shown through 3 years of disease control, impact on growth curve, and improvement in mental health.​

Review the clinical impact of mucus plugging in asthma and available evidence on changes in mucus score, mucus volume, and lung function observed in clinical studies of dupilumab.

The Hidden Impact of CLCI in Dermatology